SNSS
$0.30
Sunesis Pharmaceutic
($.01)
(1.64%)
SNSS
Earnings Whisper ®
N/A
2nd Quarter June 2020
Consensus:  ($0.05)
Revenue:  $0.15 Mil
Wednesday
Aug 12
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SNSS reports earnings?
Beat
Meet
Miss

Where is SNSS's stock price going from here?
Up
Flat
Down
Stock chart of SNSS
Analysts
Summary of analysts' recommendations for SNSS
Score
Grade
Pivots
Resistance
$0.41
$0.37
$0.34

$0.30

Support
$0.27
$0.24
$0.20
Tweet
Growth
Description
Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies.
Peers
InterCeptVertex PharmaceuticalsRegeneron PharmaceuticalsBioMarin PharmaceuticalJohnson & JohnsonZoetisBristol-Myers SquibbUltragenyx PharmaceuticalCatalentMerck & Co.